The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
Open accessAbstract
A normal hemostatic response to vascular injury requires both factor VIII (FVIII) and von Willebrand factor (VWF). In plasma, VWF and FVIII normally circulate as a noncovalent complex, and each has a critical function in the maintenance of hemostasis. Furthermore, the interaction between VWF and FVIII plays a crucial role in FVIII function, immunogenicity, and clearance, with VWF essentially serving as a chaperone for FVIII. Several novel recombinant FVIII (rFVIII) therapies for hemophilia A have been in clinical development, which aim to increase the half-life of FVIII (∼12 hours) and reduce dosing frequency by utilizing bioengineering techniques including PEGylation, Fc fusion, and single-chain design. However, these approaches have achieved only moderate increases in half-life of 1.5- to 2-fold compared with marketed FVIII products. Clearance of PEGylated rFVIII, rFVIIIFc, and rVIII-SingleChain is still regulated to a large extent by interaction with VWF. Therefore, the half-life of VWF (∼15 hours) appears to be the limiting factor that has confounded attempts to extend the half-life of rFVIII. A greater understanding of the interaction between FVIII and VWF is required to drive novel bioengineering strategies for products that either prolong the survival of VWF or limit VWF-mediated clearance of FVIII.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is thought that vWF can extend the half-life of FVIII”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Pipe et al., 2016
In the citing paper
“perhaps altered glycosylation of FVIII itself can alter its half-life or interaction with the immune system in general”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Pipe et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Gouw, S. C., van der Bom, J. G., Ljung, R., Escuriola, C., Cid, A. R., Claeyssens-Donadel, S., van Geet, C., Kenet, G., Mäkipernaa, A., Molinari, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208024 · Cited by 440
The Ashwell receptor mitigates the lethal coagulopathy of sepsis
Grewal, P. K., Uchiyama, S., Ditto, D., Varki, N., Le, D. T., Nizet, V., & Marth, J. D. (2008) · Nature Medicine · doi:10.1038/nm1760 · Cited by 374
McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278
Self-citationMurine coagulation factor VIII is synthesized in endothelial cells
Everett, L. A., Cleuren, A. C. A., Khoriaty, R. N., & Ginsburg, D. (2014) · Blood · doi:10.1182/blood-2014-02-554501 · Cited by 190
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
PETERS, R. T., TOBY, G., LU, Q., LIU, T., KULMAN, J. D., LOW, S. C., BITONTI, A. J., & PIERCE, G. F. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12076 · Cited by 126
Kannicht, C., Ramström, M., Kohla, G., Tiemeyer, M., Casademunt, E., Walter, O., & Sandberg, H. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2012.09.011 · Cited by 120
Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver
Madeira, C. L., Layman, M. E., de Vera, R. E., Fontes, P. A., & Ragni, M. V. (2009) · Blood · doi:10.1182/blood-2009-02-206979 · Cited by 37
Cited by
Lenting, P. J., Denis, C. V., & Christophe, O. D. (2017) · Blood · doi:10.1182/blood-2017-08-801662 · Cited by 269
Self-citationEvaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
Jajosky, R. P., Wu, S.-C., Zheng, L., Jajosky, A. N., Jajosky, P. G., Josephson, C. D., Hollenhorst, M. A., Sackstein, R., Cummings, R. D., Arthur, C. M., et al. (2023) · iScience · doi:10.1016/j.isci.2022.105798 · Cited by 110
Ward, S. E., O’Sullivan, J. M., Drakeford, C., Aguila, S., Jondle, C. N., Sharma, J., Fallon, P. G., Brophy, T. M., Preston, R. J. S., Smyth, P., et al. (2018) · Blood · doi:10.1182/blood-2017-06-787853 · Cited by 71
Metadata
- Authors
- Pipe, S. W., Montgomery, R. R., Pratt, K. P., Lenting, P. J., & Lillicrap, D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-10-20
- Volume
- 128
- Issue
- 16
- Pages
- 2007-2016
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2509144358
- Cited by
- 235
- References
- 9
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. https://app.cochat.ai/papers/10.1182/blood-2016-04-713289
- The paper
- Pipe, S. W., Montgomery, R. R., Pratt, K. P., Lenting, P. J., & Lillicrap, D. (2016). Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. https://doi.org/10.1182/blood-2016-04-713289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.